Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 13.73%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...